Historical failures in CNS drugs stem from treating severe, late-stage pathology. Success will come from using better biomarkers to intervene earlier and combining therapies. The speaker envisions a future of 'rational polypharmacy,' where drugs targeting different pathological drivers (e.g., excitability, inflammation) are used in concert.

The most important upcoming catalyst in neuroscience is Eli Lilly's TRAILBLAZER-ALZ 3 study, which aims to prevent Alzheimer's in at-risk patients. A positive result is expected to show a much larger effect size than seen in treating existing disease, potentially creating a massive new market and shifting the entire neurodegenerative paradigm.

The biological markers for Alzheimer's, such as amyloid protein clumps, can appear 10 to 20 years before cognitive symptoms manifest. This extensive preclinical phase makes early, non-invasive blood tests critical for identifying patients when new treatments that slow disease progression are most effective.

Al Sandrock predicts Alzheimer's treatment will shift from managing symptoms to prevention. Like cholesterol, amyloid buildup will be monitored via routine blood tests, allowing for treatment to be administered early to prevent irreversible neuron loss before cognitive impairment begins.

The focus in Alzheimer's treatment is moving from merely slowing decline in late-stage patients to early prevention. By using anti-amyloid drugs to clear plaques before significant brain damage occurs, it may be possible to prevent the disease's onset entirely.

Voyager CEO Al Sandrock suggests the 30% average efficacy of new Alzheimer's drugs isn't uniform. Instead, some patients may see a complete halt in progression while others see no benefit. He argues the next critical step is predicting these responders, which will determine whether future therapies like anti-tau agents should be added on or used as a replacement.

The next era of CNS drug development will shift from single-target therapies for late-stage disease to early intervention. This involves using biomarkers to detect disease before symptoms appear and intervening with multimodal approaches that address multiple biological pathways simultaneously, such as amyloid, tau, and metabolic deficits in Alzheimer's.

Traditional Alzheimer's drug development has heavily targeted extracellular amyloid-beta plaques with limited success. Retro Biosciences focuses upstream on cellular autophagy failure—the breakdown of the cell's natural system for recycling broken, misfolded proteins. Enhancing intracellular autophagy clears internal protein gunk before it becomes extracellular pathology, offering a biologically grounded, disease-modifying approach rather than treating visible end-stage debris.

Voyager's CEO explains that amyloid and tau are not independent culprits in Alzheimer's. Tau clumps naturally with age in a small brain region. Amyloid accumulation then acts as a trigger, causing this "tau fire" to spread catastrophically, suggesting treatments may need to address both.